Global Malignant Mesothelioma Market

Global Malignant Mesothelioma Market Size Insights Forecasts to 2035

• The Global Malignant Mesothelioma Market Size Was valued at USD 6.1 Billion in 2024
• The Global Malignant Mesothelioma Market Size is Expected to Grow at a CAGR of around 6.42% from 2025 to 2035
• The Worldwide Malignant Mesothelioma Market Size is Expected to Reach USD 12.1Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Malignant Mesothelioma Market Size Was Worth Around USD 6.1 Billion In 2024 And Is Predicted To Grow To Around USD 12.1 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 6.42% From 2025 To 2035. The global malignant mesothelioma market benefits from multiple business opportunities which include increasing need for advanced immunotherapies and targeted treatments, development of early-diagnosis technologies, expansion of clinical trials, establishment of personalized medicine, rising healthcare investments, and emerging markets which enhance treatment accessibility.

 

Market Overview

The global malignant mesothelioma market refers to the worldwide industry that develops and produces and sells therapies and diagnostics and supportive care solutions for malignant mesothelioma which is a rare and aggressive cancer that asbestos exposure causes. Additionally, the market for malignant mesothelioma treatment will experience significant growth because new immunotherapy drugs and combination treatment methods will enhance patient outcomes and increase available treatment methods. The U.S. Food and Drug Administration approved nivolumab and ipilimumab to serve as the primary treatment option for patients with unresectable malignant pleural mesothelioma, which showed a survival advantage of 18.1 months over chemotherapy treatment in the CheckMate-743 trial. The approval demonstrates that immune checkpoint blockade has gained recognition as a valid treatment method. The combination of pembrolizumab with pemetrexed and platinum chemotherapy now has approval after it demonstrated superior treatment results, which included 52 percent objective response rates and 17.3 months median survival compared to chemotherapy treatment. The regulatory results demonstrate that immunotherapy combination treatments have both clinical benefits and commercial value. Moreover, the research field currently shows strong progress through more than fifty ongoing clinical trials that study immunotherapy methods that combine with chemotherapy, new treatment drugs and immune system modulators. Researchers study different treatment methods, including PD-1/PD-L1 immune checkpoint inhibitors and CTLA-4 blockers, and new techniques, which include perioperative immunotherapy and adoptive cell therapy, to find better ways of extending patient life. Studies show that combination therapies produce better results, which include improved patient survival, than single treatment methods because dual checkpoint blockade and chemo-immunotherapy deliver better patient outcomes. The expanding treatment options from this growing pipeline will benefit patients while maintaining market expansion through the upcoming approval of new treatment methods.

 

Report Coverage

This research report categorizes the malignant mesothelioma market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the malignant mesothelioma market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the malignant mesothelioma market. 

 

Driving Factors

The global malignant mesothelioma market operates because asbestos-related cases continue to rise which creates ongoing demand for diagnostic services and treatment options. The development of immunotherapy and targeted therapy and early detection technology has led to better results for patients. Worldwide market growth receives additional support from expanding healthcare facilities, public awareness efforts and research funding.

 

Restraining Factors

The market faces two main obstacles due to expensive treatment methods and insufficient insurance coverage, which specifically impacts access to healthcare services in low- and middle-income countries. The uncommon nature of the disease prevents researchers from conducting clinical trials which results in slower progress for developing new treatments. The market experiences two major obstacles: late-stage diagnosis and aggressive tumor behavior and strict government regulations block access to new treatment methods.

 

Market Segmentation

The malignant mesothelioma market share is classified into drug type, route of administration, and distribution channel.

 

• The pemetrexed segment dominated the market in 2024, approximately 40%, and is projected to grow at a substantial CAGR during the forecast period.

Based on the drug type, the malignant mesothelioma market is divided into pemetrexed, cisplatin, carboplatin, gemcitabine, vinorelbine, and others. Among these, the pemetrexed segment dominated the market in 2024, approximately 40%, and is projected to grow at a substantial CAGR during the forecast period. The treatment has become the standard first-line therapy because it effectively treats patients when used with cisplatin and other platinum-based medications. The combination of strong clinical evidence together with proven survival advantages and medical guidelines, has led to widespread physician usage of the treatment. The product maintains its market dominance because diagnostic rates continue to rise and reimbursement policies provide necessary support for its operation.

 

• The parenteral segment accounted for the largest share in 2024, approximately 75% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the route of administration, the malignant mesothelioma market is divided into oral and parenteral. Among these, the parenteral segment accounted for the largest share in 2024, approximately 75% and is anticipated to grow at a significant CAGR during the forecast period. The primary treatment methods of chemotherapy and immunotherapy use intravenous treatment which requires hospital administration. Parenteral delivery ensures rapid drug absorption, controlled dosing, and higher bioavailability. The segment maintains its dominant market position because hospitals prefer combination treatments which include advanced biologic drugs that need infusion therapy.

• The hospital pharmacies segment accounted for the highest market revenue in 2024, approximately 60% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the malignant mesothelioma market is divided into hospital pharmacies, retail pharmacies, and oncology centers. Among these, the hospital pharmacies segment accounted for the highest market revenue in 2024, approximately 60% and is anticipated to grow at a significant CAGR during the forecast period. Hospitals provide necessary medical supervision for administering most treatments which include chemotherapy and immunotherapy. Hospitals maintain correct drug storage procedures while they handle expensive biologic medicines and they control treatment side effects. The hospital pharmacies generate increased revenue because of improved reimbursement systems and the implementation of unified oncology treatment facilities.

 

Regional Segment Analysis of the Malignant Mesothelioma Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the malignant mesothelioma market over the predicted timeframe.

North America is anticipated to hold the largest share of the malignant mesothelioma market over the predicted timeframe. The region has both high historical asbestos exposure rates and its healthcare system which achieves advanced medical results. The United States recorded approximately 2669 new mesothelioma cases during 2022 which demonstrates ongoing disease transmission that continues despite diminished asbestos usage and this situation creates a need for effective medical solutions and treatment facilities. The region possesses complete cancer treatment capabilities through its advanced medical centers which provide diagnostic services and treatment options that include immunotherapy and multimodal approaches to patients. The U.S. FDA and other regulatory bodies support clinical research activities which help North America maintain its top position in the mesothelioma treatment market through fast approval processes and new treatment adoption.

 

Asia-Pacific is expected to grow at a rapid CAGR in the malignant mesothelioma market during the forecast period. The forecast period will see market growth because of three factors the government increases its healthcare budget and more people gain access to advanced medical treatments and the developing countries of China and India have a large number of patients.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the malignant mesothelioma market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Eli Lilly and Company
• Bristol Myers Squibb (BMS)
• Merck & Co., Inc.
• Roche Holding AG
• Novartis AG
• Pfizer Inc.
• AstraZeneca plc
• Johnson & Johnson (Janssen Pharmaceuticals)
• Takeda Pharmaceutical Company
• Bayer AG
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In October 2025, The U.S. FDA granted Fast Track designation to VT3989, an investigational small-molecule therapy targeting the Hippo pathway, to accelerate its development and review for unresectable malignant mesothelioma after prior immunotherapy and chemotherapy, aiming to address unmet treatment needs.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the malignant mesothelioma market based on the below-mentioned segments: 

 

Global Malignant Mesothelioma Market, By Drug Type

• Pemetrexed
• Cisplatin
• Carboplatin
• Gemcitabine
• Vinorelbine
• Others

 

Global Malignant Mesothelioma Market, By Route of Administration

• Oral
• Parenteral

 

Global Malignant Mesothelioma Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Oncology Centers

 

Global Malignant Mesothelioma Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected growth of the Global Malignant Mesothelioma Market by 2035?

A: The market is expected to grow from USD 6.1 billion in 2024 to USD 12.1 billion by 2035, registering a CAGR of 6.42% during the forecast period 2025–2035.

 

2. Which drug segment dominated the malignant mesothelioma market in 2024?

A: The pemetrexed segment led the market in 2024 with approximately 40% share, driven by its standard first-line use in combination with platinum-based chemotherapy and strong clinical survival evidence.

 

3. Why does the parenteral route hold the largest market share?

A: Parenteral administration accounted for nearly 75% share due to widespread intravenous chemotherapy and immunotherapy use, ensuring higher bioavailability, controlled dosing, and hospital-based treatment supervision.

 

4. Which region dominates the malignant mesothelioma market and why?

A: North America holds the largest share due to high historical asbestos exposure, advanced healthcare infrastructure, strong FDA regulatory support, and increasing adoption of innovative immunotherapy-based treatment approaches.

 

5. What are the key driving factors of market growth?

A: Rising asbestos-related cases, increasing demand for advanced immunotherapies, expanding clinical trials, early diagnostic technologies, improved healthcare infrastructure, and growing research investments are major factors driving market expansion globally.